Cellular adjuvants for viral infection
US12220452B2 · kind B2 · utility
0Cited by
3References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 1, 2022 |
| Grant date | Feb 11, 2025 |
| Priority date | — |
| Expiry date | Feb 18, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/16034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.